Research firm GoodFirms said on Thursday that the hospitals are adapting various healthcare software to maintain and manage the records to reduce the viral transmission between patients and providers via the exchange of files or prescriptions during the COVID-19 crisis.
In the face of COVID-19, most healthcare departments, pharmacy companies and medical practice institutes have invested in software to keep the information confidential and secure and make it easier to get the data in just one click.
However, various health professionals and healthcare facility providers are facing challenges to pick the right tool. Therefore, GoodFirms.co has evaluated a list of Medical Practice Management, Medical Transcription, Mental Health, Chiropractic, Child Care, Dental Practice, Electronic Medical Records and Hospital Management Software.
The firm is providing Best Medical Practice Management Software, Best Medical Transcription Software, Best Mental Health Software, Best Chiropractic Management Software, Best Child Care Software, Best Dental Practice Software, Best Electronic Medical Records Software as well as Best Hospital Management Software to increase productivity and earn more revenue during the pandemic.
Citius Oncology reports positive topline results from Phase 1 clinical trial of LYMPHIR combination
CMIC agrees agentic AI partnership with Bluenote
GenomOncology partners with WeTrials to support CNS cancer clinical trials
Target ALS awards two-year research grant to AcuraStem for advancing therapeutics targeting SYF2
Ascletis reports Phase II weight‑loss results for ASC30 depot formulation
NS Pharma and NCNP report 4.5-year brogidirsen data for DMD treatment
Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment
Koselugo approved in Canada for adults with NF1 and inoperable plexiform neurofibromas
Bristol Myers Squibb reports positive Phase 3 results for oral mezigdomide in multiple myeloma
Pfizer reports positive Phase 2 results for trispecific antibody in atopic dermatitis
Agilent to acquire Biocare Medical for USD950m to expand pathology portfolio
Ipsen withdraws tazverik across all markets following safety concerns in lymphoma trial
GSK licences global rights to linerixibat to Alfasigma in USD300m deal
IDEAYA Biosciences enrols first patient in Phase 1 trial of PRMT5 inhibitor IDE892